온코퍼틸리티 시장 : 전략적 인사이트 및 예측(2026-2031년)

The Oncofertility Market is forecast to grow at a CAGR of 6.0%, reaching USD 1.63 billion in 2031 from USD 1.22 billion in 2026.

The global oncofertility market is experiencing significant expansion as healthcare providers, fertility clinics, oncology centers, and reproductive medicine organizations increasingly prioritize fertility preservation for cancer patients undergoing gonadotoxic treatments. Oncofertility is an interdisciplinary field combining oncology and reproductive medicine to preserve reproductive potential in patients receiving chemotherapy, radiotherapy, stem cell transplantation, immunotherapy, and targeted cancer therapies that may impair fertility. The market includes sperm banking, oocyte cryopreservation, embryo cryopreservation, ovarian tissue preservation, testicular tissue cryopreservation, fertility counseling, and associated reproductive technologies.

The increasing global burden of cancer among adolescents and young adults remains one of the primary drivers supporting market growth. Rising incidences of breast cancer, leukemia, lymphoma, testicular cancer, ovarian cancer, and pediatric malignancies continue increasing the number of patients at risk of treatment-related infertility. Improvements in early diagnosis and cancer treatment outcomes have significantly enhanced survival rates, increasing long-term focus on survivorship quality and future family planning. Fertility preservation is increasingly recognized as an essential component of comprehensive cancer care.

The growing awareness regarding fertility preservation options is another major factor accelerating market expansion. Healthcare providers, advocacy organizations, and oncology societies increasingly emphasize the importance of discussing fertility risks and preservation strategies before initiating cancer treatment. Oncology guidelines and survivorship programs are increasingly integrating fertility counseling and reproductive health planning into routine cancer management protocols. Early referral systems between oncologists and fertility specialists continue improving patient access to preservation services.

Advancements in cryopreservation technologies are significantly transforming the oncofertility landscape. Innovations in vitrification, controlled-rate freezing, tissue preservation, embryo freezing, and gamete storage technologies have improved preservation success rates and long-term reproductive outcomes. Oocyte cryopreservation currently represents one of the most widely adopted fertility preservation approaches because of advancements in vitrification methods and increasing clinical confidence regarding post-thaw viability and pregnancy outcomes.

The expansion of assisted reproductive technologies (ART) is another important factor influencing market growth. IVF technologies, intracytoplasmic sperm injection, embryo transfer systems, and reproductive genetic testing continue improving fertility outcomes among cancer survivors. Fertility clinics increasingly offer personalized oncofertility programs integrating reproductive endocrinology, cryopreservation, counseling, and survivorship planning to support long-term reproductive goals.

The market is also benefiting from increasing government support and healthcare policy initiatives focused on survivorship care and fertility preservation access. Several healthcare systems and insurance providers are expanding reimbursement support for fertility preservation procedures among oncology patients. Advocacy efforts continue promoting equitable access to reproductive healthcare services for young cancer survivors. Improved reimbursement frameworks are expected to strengthen long-term market adoption in developed healthcare systems.

Artificial intelligence and digital health technologies are increasingly influencing reproductive medicine and oncofertility care delivery. AI-powered reproductive analytics, embryo selection algorithms, predictive fertility modeling, telehealth fertility counseling, and digital patient management platforms are improving treatment personalization and patient engagement. Digital healthcare ecosystems are helping fertility clinics optimize clinical workflows and survivorship support services.

The increasing prevalence of delayed parenthood and declining fertility rates is also contributing to market growth. Many individuals diagnosed with cancer during reproductive years increasingly prioritize fertility preservation due to changing societal trends related to family planning and career development. This demographic shift is creating growing demand for reproductive preservation technologies and long-term cryostorage services.

The market is witnessing increasing emphasis on multidisciplinary collaboration between oncologists, reproductive endocrinologists, fertility specialists, embryologists, psychologists, and survivorship care teams. Integrated care models are improving patient education, treatment timing coordination, and personalized reproductive planning, enhancing overall clinical outcomes and patient satisfaction.

North America currently dominates the oncofertility market due to advanced fertility treatment infrastructure, strong oncology research capabilities, high assisted reproductive technology adoption, and increasing insurance support for fertility preservation services. Europe also represents a significant market supported by survivorship-focused healthcare systems and growing awareness regarding reproductive health in oncology care. Asia Pacific is expected to witness rapid growth due to rising cancer incidence, expanding fertility clinic networks, increasing healthcare investment, and growing awareness regarding fertility preservation across countries such as China, India, Japan, and South Korea.

Despite strong growth prospects, the market faces challenges related to high procedure costs, limited reimbursement in several regions, ethical considerations, shortages of trained specialists, and time-sensitive treatment coordination challenges. However, ongoing advancements in cryopreservation technologies, reproductive medicine, digital health integration, and survivorship care are expected to create substantial long-term growth opportunities for the oncofertility market.

Market Drivers

Rising Cancer Incidence Among Reproductive-Age Populations

The increasing prevalence of cancer among adolescents and young adults is one of the primary drivers supporting the oncofertility market. Chemotherapy, radiation therapy, and stem cell transplantation often carry significant risks of temporary or permanent infertility.

Healthcare systems increasingly prioritize survivorship quality and reproductive health preservation.

Growing Awareness Regarding Fertility Preservation

Awareness campaigns, oncology guidelines, and survivorship programs are improving patient understanding regarding fertility preservation options before cancer treatment initiation.

Early fertility counseling and multidisciplinary referral systems continue supporting market expansion.

Advancements in Cryopreservation Technologies

Innovations in vitrification, embryo freezing, ovarian tissue preservation, and gamete storage technologies are improving long-term fertility outcomes and procedural success rates.

Technological advancements continue strengthening clinical adoption of fertility preservation procedures.

Expansion of Assisted Reproductive Technologies

Increasing adoption of IVF, embryo transfer systems, reproductive genetic testing, and fertility preservation services is significantly supporting market growth.

Fertility clinics continue expanding personalized oncofertility treatment programs.

Increasing Focus on Survivorship and Quality of Life

Improved cancer survival rates are increasing long-term focus on emotional well-being, family planning, and reproductive health among survivors.

Oncofertility is becoming an increasingly important component of comprehensive cancer survivorship care.

Market Restraints

High Procedure and Storage Costs

One of the major restraints affecting the market is the substantial cost associated with fertility preservation procedures, cryostorage services, assisted reproductive technologies, and long-term monitoring.

Cost-related barriers may limit patient accessibility in several healthcare systems.

Limited Insurance and Reimbursement Coverage

Many countries continue facing inconsistent reimbursement frameworks for fertility preservation procedures and survivorship reproductive care.

Financial limitations may affect broader adoption of oncofertility services.

Shortage of Specialized Multidisciplinary Professionals

The market relies heavily on collaboration between oncologists, reproductive endocrinologists, embryologists, counselors, and fertility specialists.

Workforce shortages and training gaps may restrict service scalability in several regions.

Time-Sensitive Treatment Coordination Challenges

Cancer treatment often requires immediate initiation, limiting the available timeframe for fertility preservation interventions before therapy begins.

Coordinating oncology treatment with reproductive procedures remains a clinical challenge.

Technology and Segment Insights

The oncofertility market is segmented by procedure type, indication, technology, end-user, and geography. By procedure type, the market includes oocyte cryopreservation, sperm banking, embryo cryopreservation, ovarian tissue cryopreservation, and testicular tissue preservation. Oocyte cryopreservation currently accounts for a substantial market share because of increasing utilization among female cancer patients and improvements in vitrification technologies.

Sperm banking is also witnessing rapid growth because of procedural simplicity, high accessibility, and increasing awareness among male oncology patients.

Based on indication, the market includes cancer, autoimmune diseases, genetic disorders, hematologic disorders, and others. Cancer currently dominates the market due to widespread utilization of chemotherapy, radiation therapy, and stem cell transplantation associated with fertility risks.

Hematologic malignancies and pediatric oncology applications are also witnessing increasing demand for fertility preservation services.

By technology, the market includes vitrification, controlled-rate freezing, assisted reproductive technologies, AI-powered reproductive analytics, embryo monitoring systems, and reproductive genetic testing. Vitrification technologies currently dominate the market because of improved post-thaw survival rates and growing adoption in oocyte and embryo preservation procedures.

AI-powered reproductive analytics and digital fertility management systems are increasingly expanding because of growing precision medicine integration and reproductive outcome optimization.

Based on end-user, the market includes hospitals, fertility clinics, cancer centers, research institutes, and cryobanks. Fertility clinics currently dominate the market because of specialized reproductive medicine infrastructure and increasing patient demand for comprehensive preservation programs.

Hospitals and cancer centers are increasingly integrating fertility counseling and reproductive planning services into multidisciplinary oncology care frameworks.

Regionally, North America currently dominates the market due to advanced reproductive medicine infrastructure, widespread fertility preservation awareness, and strong healthcare investment. Europe also represents a major market supported by survivorship-focused healthcare policies and fertility preservation programs.

Asia Pacific is expected to witness rapid growth due to increasing cancer prevalence, expanding fertility clinic networks, and improving healthcare accessibility.

Competitive and Strategic Outlook

The oncofertility market is highly competitive and characterized by the presence of fertility clinics, reproductive technology providers, cryopreservation companies, and healthcare organizations. Key market participants include CooperSurgical, Inc., Vitrolife AB, FUJIFILM Irvine Scientific, Inc., Genea Limited, Monash IVF Group, Progyny, Inc., Merck KGaA, Cryoport, Inc., and The Prelude Network.

Leading organizations are increasingly focusing on advanced cryopreservation technologies, personalized fertility preservation programs, AI-powered reproductive analytics, and integrated survivorship care solutions to strengthen market positioning. Investments in reproductive medicine innovation, laboratory automation, and digital fertility management continue accelerating across the industry.

Strategic collaborations between oncology centers, fertility clinics, healthcare providers, and reproductive medicine companies are improving patient referral systems and treatment coordination capabilities. Partnerships involving survivorship programs, telehealth fertility counseling, and reproductive genetic testing are becoming increasingly common.

The market is witnessing increasing emphasis on patient-centered reproductive care, long-term cryostorage services, fertility counseling accessibility, and integrated oncology survivorship frameworks. Organizations capable of improving affordability, clinical outcomes, and patient education are expected to strengthen long-term market competitiveness.

Conclusion

The oncofertility market is expected to witness substantial growth due to increasing cancer incidence among reproductive-age populations, rising awareness regarding fertility preservation, and continuous advancements in cryopreservation and assisted reproductive technologies.

Advancements in reproductive medicine, AI-powered fertility analytics, digital healthcare integration, and survivorship-focused oncology care are significantly transforming fertility preservation frameworks for cancer patients. Healthcare systems increasingly prioritize quality-of-life outcomes, family planning support, and long-term survivorship care alongside cancer treatment success.

The market continues to face challenges related to high procedure costs, reimbursement limitations, workforce shortages, and time-sensitive treatment coordination. However, ongoing innovation in cryopreservation technologies, reproductive medicine, and integrated survivorship care is expected to create substantial long-term growth opportunities for the oncofertility market.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Strategic Insights
• 1.4 Analyst Recommendations

2. Disease & Epidemiology Analysis

• 2.1 Overview of Oncofertility
• 2.2 Impact of Cancer Therapies on Fertility
• 2.3 Global Cancer Incidence in the Reproductive-Age Population
  • 2.3.1 Breast Cancer
  • 2.3.2 Hematologic Malignancies
  • 2.3.3 Gynecologic Cancers
  • 2.3.4 Pediatric & Adolescent Cancers
• 2.4 Fertility Preservation Needs by Gender
  • 2.4.1 Female Fertility Preservation Demand
  • 2.4.2 Male Fertility Preservation Demand
• 2.5 Treatment-Induced Infertility Rates by Therapy Type
  • 2.5.1 Chemotherapy-Induced Gonadotoxicity
  • 2.5.2 Radiotherapy-Induced Damage
  • 2.5.3 Surgical Impact
• 2.6 Survivorship Trends and Fertility Demand
• 2.7 Unmet Needs in Oncofertility

3. Market Dynamics

• 3.1 Market Drivers
  • 3.1.1 Rising Cancer Incidence in the Young Population
  • 3.1.2 Increasing Awareness of Fertility Preservation
  • 3.1.3 Advances in Assisted Reproductive Technologies (ART)
• 3.2 Market Restraints
  • 3.2.1 High Cost of Fertility Preservation Procedures
  • 3.2.2 Limited Reimbursement Coverage
  • 3.2.3 Ethical and Cultural Barriers
• 3.3 Market Opportunities
  • 3.3.1 Expansion in Emerging Markets
  • 3.3.2 Technological Advancements in Cryopreservation
  • 3.3.3 Integration with Oncology Care Pathways
• 3.4 Market Challenges
  • 3.4.1 Lack of Standardized Guidelines
  • 3.4.2 Limited Access to Specialized Centers

4. Commercial & Market Access

• 4.1 Pricing Analysis of Fertility Preservation Services
• 4.2 Reimbursement Landscape
  • 4.2.1 Public vs Private Coverage
  • 4.2.2 Insurance Trends
• 4.3 Patient Access Programs
• 4.4 Stakeholder Analysis
  • 4.4.1 Oncology Providers
  • 4.4.2 Fertility Clinics
  • 4.4.3 Payers
• 4.5 Market Entry Barriers

5. Innovation & Pipeline Landscape

• 5.1 Overview of Innovation in Oncofertility
• 5.2 Emerging Technologies
  • 5.2.1 Ovarian Tissue Cryopreservation
  • 5.2.2 Testicular Tissue Preservation
  • 5.2.3 In Vitro Gametogenesis
• 5.3 Pipeline Analysis by Phase
  • 5.3.1 Phase I Innovations
  • 5.3.2 Phase II Developments
  • 5.3.3 Phase III Clinical Programs
• 5.4 Mechanism of Action Trends
  • 5.4.1 Gonadotropin-Releasing Hormone (GnRH) Modulation
  • 5.4.2 Cryoprotectant Advancements
• 5.5 Modality Analysis
  • 5.5.1 Pharmaceuticals
  • 5.5.2 Medical Devices & Cryopreservation Systems
  • 5.5.3 Assisted Reproductive Technologies

6. Treatment Landscape

• 6.1 Current Fertility Preservation Techniques
  • 6.1.1 Embryo Cryopreservation
  • 6.1.2 Oocyte Cryopreservation
  • 6.1.3 Sperm Cryopreservation
  • 6.1.4 Ovarian Tissue Freezing
  • 6.1.5 Testicular Tissue Preservation
• 6.2 Pharmacological Interventions
  • 6.2.1 Leuprolide Acetate (GnRH Agonist)
  • 6.2.2 Goserelin Acetate (GnRH Agonist)
  • 6.2.3 Triptorelin (GnRH Agonist)
• 6.3 Assisted Reproductive Technologies Integration
• 6.4 Clinical Guidelines & Best Practices

7. Oncofertility Market Size & Forecast

• 7.1 Global Market Size (Historical Analysis)
• 7.2 Market Forecast (2026-2031)
• 7.3 Growth Rate Analysis (CAGR)
• 7.4 Market Share by Segment
• 7.5 Scenario Analysis (Optimistic, Base, Conservative)

8. Oncofertility Market Segmentation

• 8.1 By Therapy Type
  • 8.1.1 Cryopreservation Techniques
  • 8.1.2 Pharmacological Interventions
  • 8.1.3 Assisted Reproductive Technologies
• 8.2 By Indication
  • 8.2.1 Breast Cancer
  • 8.2.2 Hematologic Malignancies
  • 8.2.3 Gynecologic Cancers
  • 8.2.4 Other Cancers
• 8.3 By Route of Administration
  • 8.3.1 Injectable
  • 8.3.2 Oral
• 8.4 By End User
  • 8.4.1 Hospitals
  • 8.4.2 Fertility Clinics
  • 8.4.3 Research Institutes

9. Geographical Analysis (Regional Level)

• 9.1 North America
  • 9.1.1 Market Size & Growth
  • 9.1.2 Demand Drivers
  • 9.1.3 Regulatory Overview
  • 9.1.4 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size & Growth
  • 9.2.2 Demand Drivers
  • 9.2.3 Regulatory Overview
  • 9.2.4 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size & Growth
  • 9.3.2 Demand Drivers
  • 9.3.3 Regulatory Overview
  • 9.3.4 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size & Growth
  • 9.4.2 Demand Drivers
  • 9.4.3 Regulatory Overview
  • 9.4.4 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size & Growth
  • 9.5.2 Demand Drivers
  • 9.5.3 Regulatory Overview
  • 9.5.4 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 United States (FDA)
• 11.2 Europe (EMA / MDR)
• 11.3 Japan (PMDA)
• 11.4 India (CDSCO)
• 11.5 China (NMPA)
• 11.6 Guidelines from Oncology & Reproductive Societies
• 11.7 Ethical & Legal Considerations

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Positioning
• 12.3 Strategic Initiatives
  • 12.3.1 Partnerships & Collaborations
  • 12.3.2 Mergers & Acquisitions
  • 12.3.3 Product Launches
• 12.4 SWOT Analysis

13. Company Profiles

• 13.1 AbbVie Inc.
  • 13.1.1 Approved Products: Leuprolide Acetate (Lupron)
  • 13.1.2 Indications: Hormone-Responsive Cancers, Fertility Preservation
  • 13.1.3 Pipeline: Verified Hormonal Therapy Developments
• 13.2 AstraZeneca PLC
  • 13.2.1 Approved Products: Goserelin Acetate (Zoladex)
  • 13.2.2 Indications: Breast & Prostate Cancer, Ovarian Suppression
  • 13.2.3 Pipeline: Oncology Hormonal Modulators
• 13.3 Ipsen Pharma
  • 13.3.1 Approved Products: Triptorelin (Decapeptyl)
  • 13.3.2 Indications: Hormone-Dependent Conditions
  • 13.3.3 Pipeline: Endocrine Therapy Programs
• 13.4 Ferring Pharmaceuticals
  • 13.4.1 Approved Products: Menotropins (Menopur), Triptorelin
  • 13.4.2 Indications: Fertility Treatments
  • 13.4.3 Pipeline: Reproductive Medicine Innovations
• 13.5 Merck KGaA (Merck Serono)
  • 13.5.1 Approved Products: Follitropin Alfa (Gonal-f), Cetrorelix
  • 13.5.2 Indications: Assisted Reproductive Technologies
  • 13.5.3 Pipeline: Fertility Hormone Therapies
• 13.6 CooperSurgical Inc.
  • 13.6.1 Approved Products: Cryopreservation Media & ART Devices
  • 13.6.2 Indications: Embryo & Oocyte Preservation
  • 13.6.3 Pipeline: Laboratory Technologies
• 13.7 Vitrolife AB
  • 13.7.1 Approved Products: Cryopreservation Solutions & IVF Media
  • 13.7.2 Indications: Embryo Culture & Freezing
  • 13.7.3 Pipeline: Advanced Reproductive Technologies
• 13.8 FUJIFILM Irvine Scientific
  • 13.8.1 Approved Products: Cryopreservation Media
  • 13.8.2 Indications: Cell & Tissue Preservation
  • 13.8.3 Pipeline: Biopreservation Solutions
• 13.9 Cook Medical
  • 13.9.1 Approved Products: Reproductive Health Devices
  • 13.9.2 Indications: ART Procedures
  • 13.9.3 Pipeline: Minimally Invasive Fertility Devices
• 13.10 Thermo Fisher Scientific
  • 13.10.1 Approved Products: Cryostorage Systems & Lab Equipment
  • 13.10.2 Indications: Biobanking & Fertility Preservation
  • 13.10.3 Pipeline: Advanced Storage Technologies

14. Future Outlook

• 14.1 Market Evolution Trends
• 14.2 Emerging Technologies Impact
• 14.3 Investment Opportunities
• 14.4 Strategic Recommendations

15. Methodology

• 15.1 Research Design
• 15.2 Data Collection Sources
• 15.3 Validation & Triangulation
• 15.4 Assumptions & Limitations